Bridge is pleased to announce our engagement with US Capital Global Securities for a $50 million equity offering. We are excited to offer eligible investors a unique opportunity to participate in this equity offering. USCG’s expertise in facilitating growth-stage investments makes them an ideal partner for this endeavor.
Press Releases
The latest press releases from bridge therapeutics
Bridge Therapeutics, today said that the MAT Act removes the outdated registration requirements on buprenorphine, making it possible for providers nationwide to prescribe it as they would any other controlled medication. Buprenorphine is a partial agonist or partial-acting opioid that treats addiction and chronic pain more safely than full-agonist opioids like morphine, oxycodone and fentanyl.
Bridge Therapeutics is delighted to announce that it achieved a Bronze Award on the Pepperdine Graziadio Business School’s fifth annual Most Fundable Companies® List. Bridge Therapeutics competed against over 4,000 of early-stage US companies to be named one of 16 finalists.
Bridge reported that Darren Prince, an internationally recognized speaker and advisor on matters of addiction and mental health recovery has joined Bridge’s commercial advisory board. He abused opioids for more than 20 years before breaking his addiction, and then went on to help many other people, in and out of the entertainment industry, struggling with opiate…
Bridge Therapeutics announced today that they were selected as one of the Top 100 startups to compete and participate in the 9th Annual Startup of the Year Summit. “The Startup of the Year competition is a great way to showcase our innovative approach to treating opioid addiction and chronic pain,” says Dr. Greg Sullivan, founder and Chief Science Officer at Bridge Therapeutics.
Birmingham, AL – April 27, 2020 – Bridge Therapeutics Inc. heard today from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application No.142396 for the Company’s lead product candidate, BT-219 (Bunalz™) is “Open and Safe to Proceed”. There were no additional questions or constraints included in the FDA’s communication. Opening…
Birmingham, AL – March 25, 2020 – Bridge Therapeutics Inc. today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Company’s lead product candidate, BT-219 (Bunalz™). BT-219, or Bunalz™, is an investigational new drug applying Catalent’s Zydis® ODT (orally disintegrating tablet) delivery technology…
Birmingham, AL – February 17, 2020 – Late last year Bridge Therapeutics Inc. (“Bridge”) completed the manufacture of clinical trial materials under Good Manufacturing Practices (GMP) at Catalent Pharmaceutical Services (“Catalent”) to use in the upcoming initial human pharmacokinetic (PK) clinical study. Subsequent to manufacture, these supplies were successfully released by Quality Assurance for use…
Catalent today announced that it has completed clinical production of Bridge Therapeutics Inc.’s (Bridge) opioid addiction development therapeutic product, BT-219, and executed an Exclusive Licensing Agreement to use Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology Catalent’s Zydis ODT technology is a unique, freeze-dried tablet that disperses almost instantly in the mouth without water. Zydis…
Bridge Therapeutics Inc. today announced that it has received feedback from the Food and Drug Administration (FDA) from a Pre-Investigational New Drug (PIND) meeting for the development of BT-219, a therapy to treat Opioid Dependence. BT-219, or Bunalz™, is an investigational new drug applying Catalent’s Zydis® ODT (orally disintegrating tablet) delivery technology to buprenorphine and naloxone,…